FPS
VNDA icon

Fieldpoint Private Securities’s Vanda Pharmaceuticals VNDA Stock Holding History

Fieldpoint Private Securities’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-300
Closed -$3K – 1719
2022
Q1 		$3K Sell
300
-160
-35% -$2.1K ﹤0.01% 1440
2021
Q4 		$7K Sell
460
-50
-10% -$871 ﹤0.01% 1190
2021
Q3 		$9K Buy
510
+90
+21% +$1.58K ﹤0.01% 1091
2021
Q2 		$7K Hold
420
– – ﹤0.01% 1134
2021
Q1 		$6K Buy
420
+60
+17% +$971 ﹤0.01% 1161
2020
Q4 		$5K Buy
+360
New +$4.33K ﹤0.01% 1139

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fieldpoint Private Securities's VNDA Position: Q2 2022 in Review

Fieldpoint Private Securities sold out of Vanda Pharmaceuticals (VNDA) in Q2 2022, closing a stake of 300 shares — an estimated $3K sold.

Fieldpoint Private Securities first reported a position in VNDA in Q4 2020 and held it in 6 quarters. The position peaked at $9K in Q3 2021. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2022.

  • Fieldpoint Private Securities reported no remaining Vanda Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Fieldpoint Private Securities sold 300 Vanda Pharmaceuticals shares in Q2 2022, an estimated $3K.
  • Fieldpoint Private Securities first reported a position in Vanda Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • Fieldpoint Private Securities's Vanda Pharmaceuticals position peaked at $9K in Q3 2021.
  • 173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.